Brittany Cote

Brian T. Hill, MD, PhD, discusses the advent of CAR T-cell therapies, such as axicabtagene ciloleucel, tisagenlecleucel, and brexucabtagene autoleucel, and how they have shifted lymphoma treatment into a new era.

Kami Maddocks, MD, discusses the significance of the selinexor approval in the diffuse large B-cell lymphoma treatment paradigm, emerging strategies that seek to address unmet needs, and remaining sequencing questions.

Pashna N. Munshi, MD, discusses the CAR T-cell therapies that have emerged in the lymphoma space and highlights the next steps for research with these products.

Peter Martin, MD, provides an overview of what the current MCL treatment paradigm looks like as well as areas of future exploration and debate.

Paul J. Shaughnessy, MD, discusses how CAR T-cell therapy is being utilized in hematologic malignancies, challenges faced with this modality, and ongoing research efforts being made to better leverage its use.

Natalie Sophia Grover, MD, discusses ongoing research with CAR T-cell therapy in hematologic malignancies, efforts examining the potential for this approach in solid tumors, and future directions and challenges with this modality.

Jesus G. Berdeja, MD, further discusses other exciting trials in multiple myeloma and CAR T therapy being presented at the 2020 ASCO Virtual Scientific Program.

Bob Valamehr, PhD, discusses the process by which a targeted CAR natural-killer cell product is engineered as well as how it will be examined in future research efforts.

Sameer Desai, MD, discusses his experience in the hematology field and how CAR T-cell therapy has evolved and its potential integration into community centers.

Himisha Beltran, MD, discusses research evaluating cell-free DNA to identify therapy resistance in prostate cancer.

Dimitrios Tzachanis, MD, PhD, discusses updates and remaining questions with CAR T-cell therapy.

Treatment with a CD19-targeted CAR-natural killer–cell therapy led to a 73% objective response rate, including 7 complete responses, in patients with relapsed/refractory non-Hodgkin lymphoma and chronic lymphocytic leukemia.

The presence of circulating tumor cell was found to be independently associated with relapse in patients with stage III melanoma, suggesting that CTC assessment may be useful in identify patients who are at risk for relapse and could benefit from adjuvant therapy.

Larry Anderson, MD, PhD, discusses emerging therapies for patients with multiple myeloma that were highlighted at the 2019 ASH Annual Meeting.

Lloyd Damon, MD, discusses the evolution of the treatment paradigm in acute lymphoblastic leukemia.